High end-of-life incidence of seizures and status epilepticus in patients with primary and secondary brain tumors - Top-Institutions - MDSpire

High end-of-life incidence of seizures and status epilepticus in patients with primary and secondary brain tumors

  • By

  • Sophie von Brauchitsch

  • Adam Strzelczyk

  • Felix Rosenow

  • Elisabeth Neuhaus

  • Daniel Dubinski

  • Joachim P. Steinbach

  • Martin Voss

  • November 3, 2022

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University Hospital Frankfurt
    University Hospital Frankfurt

    Frankfurt, Hesse

    Key Differentiators

    • Neuro-oncology
    • Epileptology
    • Neurology

  • #2

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, Massachusetts

    Key Differentiators

    • Neuro-oncology
    • Epileptology
    • Neurology

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Neuro-oncology
    • Palliative Care
    • Neurology

  • #4

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, Maryland

    Key Differentiators

    • Neuro-oncology
    • Epileptology
    • Neurology

  • #5

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Neuro-oncology
    • Epileptology
    • Neurology

Original Source(s)

High end-of-life incidence of seizures and status epilepticus in patients with primary and secondary brain tumors

  • by Sophie von Brauchitsch, Adam Strzelczyk, Felix Rosenow, Elisabeth Neuhaus, Daniel Dubinski, Joachim P. Steinbach, Martin Voss

  • November 3, 2022

Related Content

Should checkpoint inhibitors be reserved for biomarker-selected pediatric brain tumors?

Can This Device Help Neurosurgeons Better Treat Normal Pressure Hydrocephalus — and More?

A Keck Medicine of USC neurointerventionalist discusses how a minimally invasive, endovascularly implantable cerebrospinal fluid shunt is the next-generation treatment for normal pressure hydrocephalus — and possibly more.

  • by

  • March 30, 2026

  • 4 min
Current landscape and challenges of neuro-oncological molecular tumor boards in Germany: results of a nationwide follow-up survey